WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Joy Y. Wang
Patent Agent
Patents and Innovations
Palo Alto
joy.wang@wsgr.com

D650-461-7318

Download vCard
Open PDF
  • Technical Expertise

    Joy is a patent agent with extensive technical expertise in CRISPR, molecular biology, protein and nucleic acid chemistry, and gene editing.

Dr. Joy Wang is a patent agent in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovations practice. She has extensive technical expertise in CRISPR, molecular biology, protein and nucleic acid chemistry, and gene editing. Joy applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, biotechnology, and pharmaceutical industries.

Prior to joining the firm, Joy earned her Ph.D. in chemistry from UC Berkeley in the lab of Professor Jennifer Doudna, where her research focused on mechanisms of CRISPR biology, the evolution of CRISPR systems, and applications of CRISPR technology. During graduate school, she also taught several organic chemistry classes. She has co-authored publications in science journals, including Nature and Science.

Experience

Dr. Joy Wang is a patent agent in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovations practice. She has extensive technical expertise in CRISPR, molecular biology, protein and nucleic acid chemistry, and gene editing. Joy applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, biotechnology, and pharmaceutical industries.

Prior to joining the firm, Joy earned her Ph.D. in chemistry from UC Berkeley in the lab of Professor Jennifer Doudna, where her research focused on mechanisms of CRISPR biology, the evolution of CRISPR systems, and applications of CRISPR technology. During graduate school, she also taught several organic chemistry classes. She has co-authored publications in science journals, including Nature and Science.

Education
  • Ph.D., Chemistry, University of California, Berkeley, 2022

    NSF Graduate Research Fellow, UC Berkeley Chancellor’s Fellow, Outstanding Graduate Student Instructor Award

  • B.S., Chemistry, Stanford University, 2017

    Dean’s Award for Academic Achievement, Chemistry Departmental Award, Goldwater Scholar, Boothe Prize for expository and argumentative writing

Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemistry, University of California, Berkeley, 2022

    NSF Graduate Research Fellow, UC Berkeley Chancellor’s Fellow, Outstanding Graduate Student Instructor Award

  • B.S., Chemistry, Stanford University, 2017

    Dean’s Award for Academic Achievement, Chemistry Departmental Award, Goldwater Scholar, Boothe Prize for expository and argumentative writing

Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Lead author, “CRISPR technology: A decade of genome editing is only the beginning,” 379(6629) Science, 2023
  • Lead author, “Genome expansion by a CRISPR trimmer-integrase,” 618 Nature 855-861, 2023
  • Lead author, “Structural biology of CRISPR–Cas immunity and genome editing enzymes,” 20(11) Nature Reviews Microbiology 641-656, 2022
  • Lead author, “Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex,” 12(1) Nature Communications 2571, 2021
  • Co-author, “A Functional Mini-Integrase in a Two-Protein Type V-C CRISPR System,” 73(4) Molecular Cell 727-737, 2019
Insights

Select Publications

  • Lead author, “CRISPR technology: A decade of genome editing is only the beginning,” 379(6629) Science, 2023
  • Lead author, “Genome expansion by a CRISPR trimmer-integrase,” 618 Nature 855-861, 2023
  • Lead author, “Structural biology of CRISPR–Cas immunity and genome editing enzymes,” 20(11) Nature Reviews Microbiology 641-656, 2022
  • Lead author, “Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex,” 12(1) Nature Communications 2571, 2021
  • Co-author, “A Functional Mini-Integrase in a Two-Protein Type V-C CRISPR System,” 73(4) Molecular Cell 727-737, 2019
Focus Areas
  • Biotech
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Firm Advises eGenesis on Patent Matters Related to $191 Million Series D Financing
On September 4, 2024, eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney xenotransplant. The funding will also be used to advance pipeline programs as well as scale production. Wilson Sonsini Goodrich & Rosati advises eGenesis on all patent matters and advised the company on patent matters related to this Series D transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Metagenomi on IP Matters Related to $93 Million IPO
On February 13, 2024, Metagenomi, Inc., a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The shares began trading on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol “MGX.” The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.